At the same time, however, the level of putative non-DC target (tumor) cells, identified as CD11c- cells presenting the OVA-derived peptide SIINFEKL in context of MHC class I, was significantly lower in IFN-α2 and IL-2-injected tumors compared to non-injected controls on day 14 post-transfer (Fig 1D). This evidence concerns the gene ITGAX and neoplasm.